Transforming Argus Safety Configuration for Efficiency and Quality for a European Company
Proactive and well-documented follow-up in pharmacovigilance enhances case quality, ensures regulatory compliance, and strengthens signal detection and risk management for better patient safety.
Nextrove Progressive GFA automates pharmacovigilance follow-up to drive efficiency, quality and ROI.
Executive Summary
- For a top 10 global pharmaceutical company managing follow-up activities for adverse event reporting had become a significant operational challenge relying on manual coordination across teams and geographies. Repetitive queries, fragmented systems, and labor-intensive tracking processes led to reduced response rates and thousands of hours spent on administrative tasks.
- The organization required a scalable, compliant, and intelligent solution that could streamline follow-up without compromising regulatory standards
- By implementing the Nextrove automated, integrated follow-up management solution within the safety database, the company achieved significant efficiency gains, improved reporter engagement, enhanced data quality, and realized a double-digit percentage ROI—while saving operational hours.
Challenges
Significant Resource Burden
- High Volume of Manual Follow-Ups
- Labor equivalent to thousands of hours annually
- Manual tracking
- Skilled pharmacovigilance professionals spending time on administrative tasks
Repetitive and Inefficient Communication
- Reporters received standard questions, even when partial information had already been provided, thereby reducing the probability of response, increasing data management complexities due to lack of integration.
Lack of System Integration
- Responses required manual reconciliation into the safety database
- Increased risk of transcription errors and delayed case updates
Solution Approach
The transformation unfolded in three phases:
1. Assessment & Diagnostics
The company implemented Nextrove Progressive GFA, automated follow-up management module integrated directly with its safety database system.
Key Features Implemented
- Automatic case analysis to detect missing or incomplete data fields
- Automated follow-up triggers and reminders
- Custom question configuration by product and therapeutic area
- Multi-lingual, configurable query form
- Generation of fillable query form
- Fillable form and case-tailored queries sent to reporters via secure email link
- Automated ingestion of responses into the safety system
- Action item tracking and audit trail management
- All follow-up attempts, timestamps, responses, and outcomes are documented directly within the safety database, ensuring inspection readiness and compliance.
Measurable Impact
Operational Efficiency
- Thousands of hours saved annually, with projected increases as case volume grows
- Reduction in manual tracking and reconciliation activities
- Faster turnaround time for case updates
- Enhanced global consistency in follow-up practices
- Scalable framework to support growing case volumes
Data Quality Improvements
- Higher response rates
- Improved completeness of ICSRs
- Stronger data foundation for signal detection and risk assessment
Compliance and Inspection Readiness
- Full audit trail of contact attempts and responses
- Centralized documentation within the safety database
- Demonstrated due diligence during regulatory inspections
Financial Return
- More than double-digit percentage ROI
- 80% of follow-ups conducted via email
Conclusion
- This case study demonstrates that introducing Nextrove Progressive GFA in pharmacovigilance follow-up is a strategic transformation.
- By integrating intelligent case analysis, automated reminders, customizable queries, and seamless response ingestion, Nextrove Progressive GFA helps organizations to reduce operational burden, improve case quality, strengthen compliance, and achieve measurable ROI.
- In an era of increasing regulatory scrutiny and rising case volumes, Nextrove Progressive GFA represents a critical enabler of sustainable, high-quality pharmacovigilance operations.